Indication

Parathyroid carcinoma with hypercalcemia

Parathyroid carcinoma with hypercalcemia refers to a severe endocrine state arising from a rare, malignant neoplasm of the parathyroid glands that autonomous hypersecretes parathyroid hormone. Read more about Parathyroid carcinoma with hypercalcemia

19 drugs 16 manufacturers

Advertisement

Drugs that treat it

Common Parathyroid carcinoma with hypercalcemia therapies.

Showing 1–9 of 19 drugs

SENSIPAR (cinacalcet HCl)

CALCIMIMETIC, PARATHYROID CALCIUM RECEP SENSITIVITY ENHANCER·PARATHYROID CARCINOMA WITH HYPERCALCEMIA·+2
AMGEN

CINACALCET HCL

CALCIMIMETIC, PARATHYROID CALCIUM RECEP SENSITIVITY ENHANCER·PARATHYROID CARCINOMA WITH HYPERCALCEMIA·+2
CIPLA USA, INC.

CINACALCET HCL

CALCIMIMETIC, PARATHYROID CALCIUM RECEP SENSITIVITY ENHANCER·PARATHYROID CARCINOMA WITH HYPERCALCEMIA·+2
SLATE RUN PHARM

CINACALCET (cinacalcet HCl)

CALCIMIMETIC, PARATHYROID CALCIUM RECEP SENSITIVITY ENHANCER·PARATHYROID CARCINOMA WITH HYPERCALCEMIA·+2
Mylan Pharmaceuticals

CINACALCET (cinacalcet HCl)

CALCIMIMETIC, PARATHYROID CALCIUM RECEP SENSITIVITY ENHANCER·PARATHYROID CARCINOMA WITH HYPERCALCEMIA·+2
ASCEND LABORATO

CINACALCET (cinacalcet HCl)

CALCIMIMETIC, PARATHYROID CALCIUM RECEP SENSITIVITY ENHANCER·PARATHYROID CARCINOMA WITH HYPERCALCEMIA·+2
STRIDES PHARMA

CINACALCET HCL

CALCIMIMETIC, PARATHYROID CALCIUM RECEP SENSITIVITY ENHANCER·PARATHYROID CARCINOMA WITH HYPERCALCEMIA·+2
Mylan Pharmaceuticals

CINACALCET HCL

CALCIMIMETIC, PARATHYROID CALCIUM RECEP SENSITIVITY ENHANCER·PARATHYROID CARCINOMA WITH HYPERCALCEMIA·+2
Major Pharamceuticals
Filter & compare in the drug finder →Opens the drug finder with Parathyroid carcinoma with hypercalcemia preselected.

News & literature

Coming soon

Related codes

Coming soon
Coming soon

About Parathyroid carcinoma with hypercalcemia.

Parathyroid carcinoma with hypercalcemia refers to a severe endocrine state arising from a rare, malignant neoplasm of the parathyroid glands that autonomous hypersecretes parathyroid hormone.

This malignancy accounts for a small fraction of primary hyperparathyroidism cases, typically presenting in middle-aged adults without a marked sex predominance.

Pathophysiologically, the tumor drives unrestrained osteoclastic bone resorption and renal calcium reabsorption, resulting in profoundly elevated serum calcium concentrations.

Clinically, affected patients frequently exhibit pronounced constitutional fatigue, cognitive changes, nephrolithiasis, renal dysfunction, and fragile bone disease, with unregulated hypercalcemia representing the predominant source of morbidity and mortality.

Personalize your experience

Follow Parathyroid carcinoma with hypercalcemia and get updates as they land.

Create a free account

Follow an indication and get alerts when its drugs, labels, or guidelines change

Save any drug on this page to your favorites, synced across devices

AI-curated peer-reviewed research, summarized for your specialty

A morning digest of indication-relevant updates, when you want it